Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hendrix

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Alzheimer'S Research & Therapy|May 21, 2015
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysisAlireza Atri, Suzanne B Hendrix, Vojislav Pejović, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSamuel P Dickson, Benjamin A Haaland, Kent Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersGarrett B Duncan, Tyler M Duke, Samuel B Johnson, et al.
The Journal of Prevention of Alzheimer'S Disease|December 7, 2017
A Novel Eigenvector-based Method to Detect Mild Alzheimer's Disease Using Event-Related PotentialsB L Brown, S B Hendrix, M Cecchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1995
FDG-SPECT: correlation with FDG-PETW H Martin, D Delbeke, J A Patton, et al.
International Psychogeriatrics|March 19, 2025
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysisSuzanne B Hendrix, Mary Sano, Constantine Lyketsos, et al.
Biomarkers in Medicine|May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification processSuzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJoseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
Neurology and Therapy|September 17, 2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying TherapiesSamuel P Dickson, Craig H Mallinckrodt, Basia Rogula, et al.
The Journal of Prevention of Alzheimer'S Disease|July 24, 2024
Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of "Time Saved"S P Dickson, A Solomon, M Kivipelto, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Alzheimer'S Research & Therapy|May 21, 2015
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysisAlireza Atri, Suzanne B Hendrix, Vojislav Pejović, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSamuel P Dickson, Benjamin A Haaland, Kent Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersGarrett B Duncan, Tyler M Duke, Samuel B Johnson, et al.
The Journal of Prevention of Alzheimer'S Disease|December 7, 2017
A Novel Eigenvector-based Method to Detect Mild Alzheimer's Disease Using Event-Related PotentialsB L Brown, S B Hendrix, M Cecchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1995
FDG-SPECT: correlation with FDG-PETW H Martin, D Delbeke, J A Patton, et al.
International Psychogeriatrics|March 19, 2025
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysisSuzanne B Hendrix, Mary Sano, Constantine Lyketsos, et al.
Biomarkers in Medicine|May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification processSuzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJoseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
Neurology and Therapy|September 17, 2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying TherapiesSamuel P Dickson, Craig H Mallinckrodt, Basia Rogula, et al.
The Journal of Prevention of Alzheimer'S Disease|July 24, 2024
Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of "Time Saved"S P Dickson, A Solomon, M Kivipelto, et al.
Pageof 6